Clinical Trials Logo

Overactive Bladder clinical trials

View clinical trials related to Overactive Bladder.

Filter by:

NCT ID: NCT02922842 Terminated - Overactive Bladder Clinical Trials

A Study of Transcutaneous Electrical Nerve Stimulation for Overactive Bladder

Start date: July 2016
Phase: N/A
Study type: Interventional

The purpose of the study is to compare patient centered- outcomes between Transcutaneous Electrical Nerve Stimulation (TENS) at three locations to treat urinary urge incontinence. One of these locations will be along the tibial nerve, which is traditionally accessed near the medial malleolus. The second site will be on the sacral nerve which is accessed over the sacrum. The third site will be a sham site on the shoulder. This study will evaluate the feasibility of transcutaneous electrical stimulation in the treatment of overactive bladder.

NCT ID: NCT02865395 Terminated - Overactive Bladder Clinical Trials

Timing of B and O Suppositories to Help Relieve Post-operative Bladder Spasms

Start date: March 2016
Phase: Phase 4
Study type: Interventional

Ureteroscopy is a common procedure in Urology that patients undergo daily to deal with a variety of ailments. These procedures often require that the bladder be filled and emptied with sterile water or saline several times during the procedure, and often result in the patient receiving a catheter at the end of the procedure. One common side effect is that patients experience bladder spasm or discomfort for a period of time after these procedures. Belladonna and Opium (B and O) suppositories and PO Oxybutynin are often given in the post-operative setting to relieve these symptoms. The principle objectives of this study are: 1. To determine if the addition of a B and O supprette suppository at the end of cystoscopic/ureteroscopic procedures reduces the incidence of bladder spasms and urinary discomfort that patients experience in the post-operative setting. 2. To determine if using peri-operative B and O supprette suppositories reduces the need for pos-operative oral Ditropan and use of narcotic pain medications.

NCT ID: NCT02805452 Terminated - Overactive Bladder Clinical Trials

Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer

VesiCaP
Start date: July 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether Succinate of Solifenacin reduces the OverActive Bladder syndrome occurring during prostate irradiation.

NCT ID: NCT02660359 Terminated - Clinical trials for Urinary Incontinence

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2

CONTENT2
Start date: July 8, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult subjects treated for neurogenic detrusor overactivity (NDO) due to spinal cord injury (SCI) or multiple sclerosis (MS).

NCT ID: NCT02660138 Terminated - Clinical trials for Urinary Incontinence

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1

CONTENT1
Start date: March 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult subjects treated for neurogenic detrusor overactivity (NDO) due to spinal cord injury (SCI) or multiple sclerosis (MS).

NCT ID: NCT02398578 Terminated - Overactive Bladder Clinical Trials

Cystoscopic Ablation Via RF Energy Clinical Trial

CARETI
Start date: February 2015
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II study to assess the safety and performance of the Amphora OAB system for treatment of urgency and frequency with or without urge incontinence caused by an overactive bladder.

NCT ID: NCT02179099 Terminated - Overactive Bladder Clinical Trials

Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients

Start date: July 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm pilot study evaluating the feasibility and preliminary safety of a single intravesical instillation of TC-3 gel mixed with botulinum toxin (BTX) for symptomatic improvement in overactive bladder patients.

NCT ID: NCT02129816 Terminated - Overactive Bladder Clinical Trials

Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder

BryoSoliP
Start date: May 2014
Phase: Phase 2/Phase 3
Study type: Interventional

Overactive bladder (OAB) is an enigmatic condition that is treated symptomatically with anticholinergic drugs (gold standard 2013). In a clinical pilot study was found to be a trend for a higher reduction of the micturition frequency in the Bryophyllum pinnatum group - treated with chewing tablets containing 50% of dried BP leaf press juice - than in the placebo group (n=20, p=0.064) Hypothesis: To test the superior effectivity of Bryophyllum versus Placebo in the treatment of OAB with the needed number (Purpose 1) and to assess in an experimental arm the side effects of BP in comparison to the standard drug (Vesicare) in a clincial trial (Purpose 2).

NCT ID: NCT02070042 Terminated - Overactive Bladder Clinical Trials

Oxybutynin and Omega-3 for OAB (Overactive Bladder)

Start date: February 2014
Phase: N/A
Study type: Interventional

We aim to evaluate whether the addition of Omega-3 fatty acids to oxybutynin, a standard first-line treatment for overactive bladder syndrome, will improve symptoms and quality of life. Secondarily, we will evaluate whether Omega-3 fatty acids help reduce the adverse effects of oxybutynin. Hypothesis - Primary: Omega-3 will enhance the beneficial role of oxybutynin in the treatment of overactive bladder (OAB) - Secondary: Omega-3 will reduce the side effects of dry eyes and constipation associated with oxybutynin

NCT ID: NCT01972061 Terminated - Overactive Bladder Clinical Trials

Foot/Hand Neuromodulation for Overactive Bladder (OAB)

FootStim
Start date: March 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if electrical stimulation of the foot is effective in the treatment of overactive bladder conditions.